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Abstract
Ideally, a clinical trial should be able to demonstrate not only a statistically significant improvement
in the primary efficacy endpoint, but also that the magnitude of the effect is clinically relevant. One
proposed approach to address this question is a responder analysis, in which a continuous primary
efficacy measure is dichotomized into "responders" and "non-responders." In this paper we discuss
various weaknesses with this approach, including a potentially large cost in statistical efficiency, as
well as its failure to achieve its main goal. We propose an approach in which the assessments of
statistical significance and clinical relevance are separated.
Background
A clinical endpoint used to determine the efficacy of an
experimental treatment can be measured on a variety of
scales, including a continuous scale, an ordinal scale, or a
binary scale. One important goal common to many clini-
cal trials is determining whether or not the effect of the
experimental treatment is significantly better than that of
the control treatment, and this goal can be achieved using
measurements based on any of these scales. However, it is
not only important to assess statistical significance, but
also to assess the clinical relevance of the effect, and the
assessment of clinical relevance has received much less
attention in the statistical literature. The purpose of this
paper is to discuss some of the issues associated with the
assessment of clinical relevance, focusing in particular on
an approach known as the "responder analysis" that
involves dichotomizing a continuous or ordinal variable
into a binary variable.
One potential approach to assess clinical relevance is to
define a clinically relevant effect, and test the null hypoth-
esis that the true effect is of this size or less versus the
hypothesis that the true effect is greater than the clinically
relevant effect. For example, suppose that the clinical end-
point is a continuous variable, X, such that larger values
represent better efficacy, and that there is interest in the
mean difference in this endpoint, µ, between the experi-
mental treatment and the control. Note that X could rep-
resent a measurement taken at the conclusion of the trial
or a change in that measurement from its baseline value.
The typical null hypothesis (assuming one-sided testing)
is that of no difference, or µ ≤ 0, versus the alternative
hypothesis µ > 0. However, if one were to define a mini-
mum clinically important difference, µ0, then one could
test the null hypothesis µ  ≤  µ0 versus the alternative
hypothesis µ > µ0. This hypothesis is sometimes referred
to as "super superiority," and a statistically significant
result in this case would imply both statistical significance
and clinical relevance. However, the "super superiority"
null hypothesis is not frequently used in practice, proba-
bly due to concerns with decreased power.
Published: 25 October 2007
Trials 2007, 8:31 doi:10.1186/1745-6215-8-31
Received: 28 May 2007
Accepted: 25 October 2007
This article is available from: http://www.trialsjournal.com/content/8/1/31
© 2007 Snapinn and Jiang; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Trials 2007, 8:31 http://www.trialsjournal.com/content/8/1/31
Page 2 of 6
(page number not for citation purposes)
Probably the most common approach to assess clinically
relevance is to compare the observed treatment effect with
the minimum clinically important difference. That is, sta-
tistical significance is based on a test of the null hypothe-
sis of no difference, and clinical relevance is concluded if
the observed treatment effect,  , is greater than µ0.
Another approach also in common use, which we refer to
as a responder analysis, is based on defining a threshold
value above which a subject is considered to be a
"responder," and below which a subject is considered to
be a "non-responder." If we let x0 represent the threshold
value, then 
is a binary variable indicating whether or not the subject
is a responder. Now let pX and pC be the response rates in
the experimental group and the control group, respec-
tively. The null hypothesis for the responder analysis,
therefore, is pX ≤ pC, and the alternative is pX > pC. As in the
case of "super superiority," if the responder null hypothe-
sis is rejected then both statistical significance and clinical
relevance are concluded.
Some examples of this approach in the medical literature
include the following. Eron et al [1] compared fosampre-
navir-ritonavir to lopinavir-ritoavir in HIV-1-infected sub-
jects, and one of the primary endpoints was the
achievement of HIV-1 RNA less than 400 copies per mL at
week 48. Tyring et al [2] compared etanercept with pla-
cebo in subjects with moderate to severe psoriasis, and the
primary endpoint was a 75% or greater improvement
from baseline in psoriasis area and severity index score
(PASI 75) at week 12. Edwards et al [3] compared oral
methotrexate, rituximab, rituximab plus cyclophospha-
mide and rituximab plus methotrexate in subjects with
active rheumatoid arthritis, and the primary endpoint was
the achievement of an ACR 50 response at week 24. An
ACR 50 response was defined as an improvement of at
least 50 percent from baseline in counts of both tender
and swollen joints, as well as in three of five other disease-
activity measures. McMillan-Price et al [4] compared 4
reduced-fat, high-fiber diets in overweight or obese young
adults, and the reported results included a comparison of
the proportions of subjects who lost 5% or more of body
weight over 12 weeks.
This responder approach is also described in regulatory
guidance documents. For example, a recent draft guidance
from the FDA on patient-reported outcomes [5] specifi-
cally endorsed the responder analysis as an alternative
approach to assessing clinical relevance:
Page 19, Defining a minimum important differ-
ence:"Many PRO instruments are able to detect mean
changes that are very small; accordingly it is important to
consider whether such changes are meaningful. Therefore,
it is appropriate for a critical distinction to be made between
the mean effect seen (and what effect might be considered
important) and a change in an individual that would be
considered important, perhaps leading to a definition of a
responder."
Page 20, Definition of responders: "There may be situa-
tions where it is more reasonable to characterize the mean-
ingfulness of an individual's response to treatment than a
group's response, and there may be interest in characteriz-
ing an individual patient as a responder to treatment, based
upon prespecified criteria backed by empirically derived evi-
dence supporting the responder definition as a measure of
benefit. Such examples include categorizing a patient as a
responder based upon a prespecified change from baseline
on one or more scales; a change in score of a certain size or
greater (e.g., a 2-point change on an 8-point scale); or a
percent change from baseline."
Page 25, Planning for Study Interpretation: "In some
cases, the FDA may request an a priori definition of the
minimum observed difference between treatment group
means (i.e., MID) that will serve as a benchmark to inter-
pret whether study findings are conclusive. In other cases,
the FDA may request an a priori definition of a treatment
responder that can be applied to individual patient changes
over time."
In addition, a recent guidance from the Committee for
Medicinal Products for Human Use [6] concerning non-
inferiority trials included the following:
Page 6, Demonstrating Efficacy: "Establishing a clini-
cally relevant benefit over placebo is accomplished by con-
sidering the point estimate of the difference between the test
product and placebo and assessing its clinical relevance,
either using the original scale or by considering responder
rates.... A judgement must be made regarding whether the
difference seen is clinically useful."
Although the responder analysis is in common use, it has
substantial disadvantages, and even its benefits do not
stand up to careful scrutiny. Therefore, the purpose of this
paper is to examine this approach in some detail.
Methods
Cost in Power
One well-known disadvantage of the responder analysis is
reduced power relative to an analysis on the original scale
[7-9]. Consider a simple model in which the measure-
ment, X, is a normally distributed variable with known
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variance. Without loss of generality, assume unit variance,
a true mean value in the control group of -µ/2, and a true
mean value in the experimental group of µ/2. Under this
model, power and sample size for a comparison of the
means of the two groups are completely determined by µ,
but the power and sample size for a comparison of
responder rates depend both on µ  and the threshold
value, x0.
Table 1 illustrates the impact on the required sample size
for 90% power under this model. Clearly, the major factor
affecting sample size for both approaches was µ, the true
mean difference between the two groups. As µ increased
from 0.2 to 1.0, the sample size required to detect a mean
difference between groups decreased from 526 subjects
per group to 21. The threshold value, x0, also had a major
impact on the sample size for the responder analysis. The
required sample size was minimized when the threshold
value fell midway between the mean values for the two
treatment groups; i.e., x0 = 0. However, even in this case,
the sample size requirement for the responder analysis
was far greater than for the test of a mean difference, with
a relative increase of approximately 60%. As the threshold
value moved away from the midway point, the difference
between the sample size requirements for the two
approaches increased greatly. For example, with a mean
difference between groups of 0.2 units and a threshold
value of x0 = 2, which corresponds to responder rates of pX
= 2.9% and pC = 1.8%, the sample size requirement for the
responder analysis is 4053 subjects per group, or nearly an
8-fold increase over the 526 subjects per group required to
detect a difference in means.
Note that under different models the impact on power
and sample size could be smaller, and indeed there may
be cases where the responder analysis has greater power
than an analysis based on the continuous variable. How-
ever, these situations usually lead to difficulties in inter-
pretation of the results whichever analysis is used, as we'll
discuss below.
While this impact on sample size in the normally distrib-
uted case is quite large, it could certainly be acceptable if
the benefit of the responder analysis, that is, its ability to
help ensure a clinically important treatment effect, were
real. However, as we'll discuss below, this purported ben-
efit is largely illusory.
Other Problems with the Responder Analysis
Perhaps the main problem with the responder analysis is
the arbitrary nature of the definition of a response [10].
Clearly, there are some situations where the achievement
of a certain value on a continuous scale has enormous
clinical implications, such as when a test value is used as
the basis for a decision on hospital admission or surgical
intervention. In these cases, an analysis of the response
rates would be highly relevant despite any cost in power.
Alternatively, the clinical event itself (i.e., the hospitaliza-
tion or the surgery) would make an appropriate endpoint
for determining the treatment effect. However, in most
cases the cutoff value used to determine a responder is an
arbitrary point on a continuous scale. For example, in the
cases presented earlier, there is probably very little clinical
difference between the achievement of 399 versus 401
copies per mL of HIV-1 RNA, or between a weight loss of
4.9% versus 5.1%. However, there may be great differ-
ences in clinical relevance within the responder and non-
responder groups; for example, the differences between a
weight loss of 5.1% versus 20%, and between a loss of
4.9% versus a gain of 10%, are probably quite relevant. In
fact, it's the loss of information associated with lumping
these groups together that leads to the decreased efficiency
and increased sample size requirements described above.
It is also interesting to consider the inconsistent applica-
tion of the responder analysis. There are some disease
Table 1: Sample Size Required for 90% Power to Detect a Difference in Means or a Difference in Responder Rates
µ x0 Responder Rates Per Group Sample Per Group Sample
pX pC Size – Difference in Means Size – Difference in Rates
0.2 0 54.0% 46.0% 526 827
0.2 1 18.4% 13.6% 526 1204
0.2 2 2.9% 1.8% 526 4053
0.5 0 59.9% 40.1% 84 133
0.5 1 22.7% 10.6% 84 197
0.5 2 4.0% 1.2% 84 689
1.0 0 69.1% 30.9% 21 34
1.0 1 30.9% 6.7% 21 53
1.0 2 6.7% 0.6% 21 200Trials 2007, 8:31 http://www.trialsjournal.com/content/8/1/31
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areas where the use of a responder analysis is expected (for
example, the use of a specific ACR cutoff such as ACR 50
in rheumatoid arthritis) and others where it is unusual
(for example, percent change from baseline in bone min-
eral density in subjects with osteoporosis). Given the sub-
stantial cost in efficiency associated with the responder
analysis it seems that there should be a clear rationale for
the situations where it is or is not appropriate. The simple
desire to assess the clinical relevance of the treatment
effect must not be a sufficient criterion, since clinical rele-
vance is important in every clinical setting, while the use
of the responder analysis is sporadic. However, there does
not appear to be any other clear criterion.
It is also interesting to consider the meaning of the term
"responder" in the context of a controlled clinical trial. In
many clinical settings the outcome measurement may
improve over time for reasons unrelated to the study treat-
ment. Some causes might include regression to the mean,
measurement error, natural history of the disease, or ther-
apies taken by the subject other than the study therapy. Of
course, this is the primary reason for the inclusion of a
control group. However, the term "responder" seems to
imply a belief that the improvement in the outcome meas-
urement on a particular subject was caused by the experi-
mental treatment. A more appropriate definition of
response (i.e., a causal effect) would be based on the out-
come of an individual subject when taking the experimen-
tal treatment relative to the outcome that subject would
have experienced with a placebo. However, this type of
information is not available in standard parallel-group
clinical trials. In fact, in such trials the true causal effect of
the treatment (i.e., the effect beyond that which a placebo
would have produced) can only be assessed by a compar-
ison of the groups.
Consider the case of a placebo-controlled trial in which a
large fraction of the subjects in the experimental group
responded (say, 30%), but the response rate was identical
in the placebo group. In such a case it would seem likely
that none of the "responses" were due to the activity of the
experimental therapy, and so it would seem inappropriate
to refer to any of these subjects as "responders."
Finally, recall one of the key drivers for the use of a
responder analysis from the FDA guidance document: tri-
als may have the ability to detect small mean changes that
are not clinically relevant. However, the responder analy-
sis actually suffers from exactly the same problem. Note
that the hypotheses µ  ≤ 0 and pX ≤ p C are both null
hypotheses of no difference between groups; therefore, in
both cases, rejecting the null hypothesis simply rules out
a zero difference between groups. In fact, in the case of dis-
tributions in the treatment and control populations that
differ only in location (such as in the case of two normally
distributed distributions with identical variance), the two
hypotheses are identical: rejecting either one implies that
the other is rejected as well. Just as in a test for mean dif-
ferences between treatment groups, with a large enough
sample size any arbitrarily small difference between treat-
ment groups in response rates can result in statistical sig-
nificance, regardless of the rigor or lack of rigor in the
definition of a responder. Therefore, rejection of the null
hypothesis of equal response rates in no way guarantees
that the effect of the treatment is clinically meaningful.
Results and discussion
The goal of determining whether or not a treatment effect
is clinically meaningful is certainly an important one, but
the responder analysis alone does not accomplish it. Just
as in the test for a mean difference between groups, the
null hypothesis for the responder analysis is of no differ-
ence between groups. Therefore, rejection of either null
hypothesis simply allows one to conclude that there is a
non-zero difference between the groups, not that the dif-
ference is clinically meaningful. Given the substantial cost
in efficiency associated with this analysis in many cases,
the responder analysis should typically be avoided as the
primary analysis approach.
How, then, does one achieve the goal of determining
whether or not a treatment effect is clinically meaningful?
Unless one is willing to define a "super superiority"
hypothesis, then the approach should be to separate the
questions of statistical significance and clinical impor-
tance. In order to achieve this goal, the first step is to deter-
mine whether or not the treatment effect is real through
the use of a statistical hypothesis test. This should typi-
cally be based on the original, continuous scale, but if
there is reason to believe that the responder analysis has
greater power than the analysis of the continuous data
then the responder analysis could be considered. The next
step is to determine clinical importance by examination of
the mean difference between groups, as well as by exami-
nation of response rates, possibly using various response
definitions.
However, the assessment of both statistical significance
and clinical importance can be complicated by the nature
of the distributions of response. First, take the simplest
case of two normal distributions with identical variances
but different means. Figure 1 illustrates the density func-
tions for the experimental treatment (the dashed line) and
the control (the solid line), and Figure 2 illustrates their
cumulative distribution functions. (In both figures the x-
axis is the continuous response variable, with greater val-
ues indicating greater efficacy, and the vertical line in Fig-
ure 1 represents a hypothetical threshold.) In this case, the
two null hypotheses (µ ≤ 0 and pX ≤ pC) are identical, and
the existence of a mean difference implies the existence ofTrials 2007, 8:31 http://www.trialsjournal.com/content/8/1/31
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difference in response rates, and vice versa; therefore, the
same test, such as a t-test, could be used to test either
hypothesis. The consistent horizontal separation between
the distribution functions (Figure 2) suggests that the ben-
efit on the continuous scale was consistent among sub-
jects, although it should be recognized that other
explanations are possible. If the assumption of a consist-
ent benefit among subjects seems reasonable, the mean
difference between groups would be an appropriate sum-
mary of the treatment benefit, and its magnitude should
be used to help determine clinical relevance. In addition,
the vertical distance between the curves is a measure of the
difference in responder rates for a specific threshold value.
Since the vertical difference will always differ for different
threshold values (unless the curves completely overlap
and the difference is always zero), it makes sense to eval-
uate multiple threshold values to help assess clinical rele-
vance.
Contrast this with Figures 3 and 4, in which the variances
differ between the two groups, resulting in an inconsist-
ency between the mean difference and the difference in
response rates. In this case, the means of the two distribu-
tions are identical, while the experimental treatment has a
higher response rate. This is obviously a case where an
analysis based on response rates would have greater
power than an analysis based on the mean difference.
However, the analysis and interpretation in this case are
considerably more complicated than in the case of equal
variances. First, the assessment of statistical significance
based on the continuous variable must take into account
the nature of the distributions. (Note that the common t-
test assumes equal variances, and so would be inappropri-
ate in this case.) In addition, the observed mean difference
between groups does not appear to be a satisfactory sum-
mary statistic in this case since examination of Figure 4
suggests that the treatment effect is inconsistent from sub-
ject to subject. In fact, it appears as though some subjects
benefit from the treatment while others are harmed.
Assessment of clinical significance in this case can be dif-
ficult. While examination of response rates can be helpful,
is should be emphasized that, due to the arbitrary nature
of any specific cutoff value, various definitions of
response should be used.
Of course, the distributions of responses may differ in
considerably more complex ways than illustrated here. In
addition, due to limited sample sizes, it may be difficult
to tell whether the horizontal difference between two
empirical distribution functions suggests a consistent
effect from patient to patient. Despite these limitations,
examination of the empirical distribution functions
should provide valuable information that simple compar-
isons of means or response rates do not provide.
Distribution of Outcomes in the Experimental Group  (Dashed Line) Has Equal Mean Value to That of the Control  Group (Solid Line), But a Greater Proportion of Responders Figure 3
Distribution of Outcomes in the Experimental Group 
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Distribution of Outcomes in the Experimental Group  (Dashed Line) Has Greater Mean Value Than Control Group  (Solid Line) And Greater Proportion of Responders Figure 1
Distribution of Outcomes in the Experimental Group 
(Dashed Line) Has Greater Mean Value Than Control Group 
(Solid Line) And Greater Proportion of Responders.
Cumulative Distribution Functions for Two Treatment  Groups When the Outcome Variable Distributions Differ in  Mean But Not Variance; Horizontal Displacement Repre- sents the Mean Difference and Vertical Displacement Repre- sents the Difference in Response Rates Figure 2
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Until now we have assumed the original response variable
is continuous, but the same arguments apply when the
response variable is ordinal. A responder analysis can be
defined by dichotomizing the ordinal scale, but an analy-
sis of the ordinal variable using, say, a proportional odds
model, will typically have considerably greater power.
Conclusion
In conclusion, the main disadvantage of the responder
analysis, its reduced efficiency relative to an analysis of the
original continuous variable, is well-known, but the other
weaknesses of the responder analysis highlighted in the
paper are less well-known. The recommended approach
to assess statistical significance and clinical relevance
should be sequential, with statistical significance based on
the most powerful approach (usually using the continu-
ous variable) and clinical relevance based on examination
of the mean difference between groups and on response
rates. It is also important to examine the cumulative dis-
tribution functions to help assess the consistency of
response among subjects.
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